TrovaGene, Inc. (TROV) EPS Estimated At $-0.08; Seaworld Entertainment Has 1.33 Sentiment

May 8, 2018 - By Maria Brooks

TrovaGene, Inc. (NASDAQ:TROV) Logo

Seaworld Entertainment Inc (SEAS) investors sentiment decreased to 1.33 in 2017 Q4. It’s down -0.20, from 1.53 in 2017Q3. The ratio has dropped, as 77 investment professionals increased and opened new positions, while 58 decreased and sold their positions in Seaworld Entertainment Inc. The investment professionals in our database reported: 67.60 million shares, down from 68.16 million shares in 2017Q3. Also, the number of investment professionals holding Seaworld Entertainment Inc in top ten positions decreased from 2 to 1 for a decrease of 1. Sold All: 25 Reduced: 33 Increased: 46 New Position: 31.




Analysts expect TrovaGene, Inc. (NASDAQ:TROV) to report $-0.08 EPS on May, 9.They anticipate $0.18 EPS change or 69.23% from last quarter’s $-0.26 EPS. After having $-0.06 EPS previously, TrovaGene, Inc.’s analysts see 33.33% EPS growth. The stock decreased 1.05% or $0.003 during the last trading session, reaching $0.282. About 222,615 shares traded. TrovaGene, Inc. (NASDAQ:TROV) has declined 66.35% since May 8, 2017 and is downtrending. It has underperformed by 77.90% the S&P500.

Among 8 analysts covering TrovaGene (NASDAQ:TROV), 1 have Buy rating, 1 Sell and 6 Hold. Therefore 13% are positive. TrovaGene had 19 analyst reports since August 14, 2015 according to SRatingsIntel. The company was downgraded on Monday, April 25 by Piper Jaffray. Maxim Group maintained it with “Buy” rating and $4.0 target in Wednesday, August 16 report. The firm has “Buy” rating given on Monday, June 12 by Maxim Group. The rating was maintained by Maxim Group on Tuesday, August 22 with “Buy”. Maxim Group maintained it with “Buy” rating and $400 target in Thursday, August 10 report. H.C. Wainwright maintained the shares of TROV in report on Tuesday, March 6 with “Buy” rating. As per Thursday, March 16, the company rating was downgraded by PiperJaffray. The stock of TrovaGene, Inc. (NASDAQ:TROV) has “Market Perform” rating given on Tuesday, March 29 by Avondale. The rating was downgraded by Leerink Swann to “Sector Perform” on Tuesday, April 26. The rating was initiated by Cantor Fitzgerald with “Buy” on Tuesday, September 15.

Another recent and important TrovaGene, Inc. (NASDAQ:TROV) news was published by Streetinsider.com which published an article titled: “Trovagene (TROV) Announces Presentations at AACR” on April 12, 2018.

Investors sentiment decreased to 0.53 in 2017 Q4. Its down 0.32, from 0.85 in 2017Q3. It turned negative, as 7 investors sold TrovaGene, Inc. shares while 10 reduced holdings. 3 funds opened positions while 6 raised stakes. 2.44 million shares or 51.68% less from 5.05 million shares in 2017Q3 were reported. Tci Wealth Inc invested in 300 shares or 0% of the stock. Cambridge Advsrs Inc invested 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV). Raymond James Assoc owns 23,000 shares for 0% of their portfolio. California Public Employees Retirement System holds 0% or 77,200 shares in its portfolio. Captrust Financial Advisors holds 0% or 62,500 shares. Bnp Paribas Arbitrage stated it has 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV). 56,052 are owned by Northern. Northwestern Mutual Wealth Management holds 3,400 shares or 0% of its portfolio. Elkhorn Ptnrs Partnership invested 0.06% in TrovaGene, Inc. (NASDAQ:TROV). Barclays Public Ltd Company reported 25,000 shares. Savings Bank Of Mellon holds 0% of its portfolio in TrovaGene, Inc. (NASDAQ:TROV) for 56,488 shares. Meeder Asset Mngmt accumulated 5,433 shares. Deutsche Bank & Trust Ag reported 0% in TrovaGene, Inc. (NASDAQ:TROV). State Bank Of America De owns 5,825 shares for 0% of their portfolio. Commercial Bank Of Montreal Can holds 22,500 shares.

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring technology in tumor genomics. The company has market cap of $16.75 million. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. It currently has negative earnings. The PCM-075 is an orally bioavailable, which has explored in preclinical antitumor activity as a single agent and in synergy combinations with approximately 10 different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib, a development stage FLT3 inhibitor, and Velcade (bortezomib) in acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer, and other liquid and solid tumor cancers.

Olstein Capital Management L.P. holds 1.94% of its portfolio in SeaWorld Entertainment, Inc. for 1.12 million shares. Managed Asset Portfolios Llc owns 384,440 shares or 1.65% of their US portfolio. Moreover, Walthausen & Co. Llc has 1.5% invested in the company for 1.17 million shares. The Pennsylvania-based Penn Capital Management Co Inc has invested 0.89% in the stock. New Jersey Better Educational Savings Trust, a New Jersey-based fund reported 34,000 shares.

SeaWorld Entertainment, Inc., together with its subsidiaries, operates as a theme park and entertainment firm in the United States. The company has market cap of $1.40 billion. The firm operates marine-life theme park under the SeaWorld brand name in San Diego, Orlando, and San Antonio; Busch Gardens theme parks, which are family-oriented destinations with foreign geographic settings in Tampa and Williamsburg; and water parks under the Aquatica brand in Orlando, San Antonio, and San Diego. It currently has negative earnings. It also operates the Adventure Island name in Tampa; Water Country USA name in Williamsburg; Discovery Cove marine life theme park in Orlando; and Sesame Place, a seasonal park in Langhorne.

Since January 1, 0001, it had 3 buys, and 0 sales for $12.03 million activity.

Ratings analysis reveals 83% of SeaWorld Entertainment’s analysts are positive. Out of 6 Wall Street analysts rating SeaWorld Entertainment, 5 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5.5 while the high is $20.0. The stock’s average target of $13.83 is -12.74% below today’s ($15.85) share price. SEAS was included in 6 notes of analysts from September 2, 2016. The firm earned “Buy” rating on Thursday, September 22 by Citigroup. SunTrust initiated the stock with “Buy” rating in Thursday, April 13 report. Dougherty & Company maintained SeaWorld Entertainment, Inc. (NYSE:SEAS) rating on Friday, September 2. Dougherty & Company has “Buy” rating and $5.5 target. The firm has “Outperform” rating given on Wednesday, December 14 by Macquarie Research. The rating was initiated by Goldman Sachs with “Sell” on Thursday, April 6. The firm earned “Outperform” rating on Wednesday, November 9 by FBR Capital.

More recent SeaWorld Entertainment, Inc. (NYSE:SEAS) news were published by: Bizjournals.com which released: “SeaWorld Orlando shares debut date for new Aquatica attraction (Video)” on May 07, 2018. Also Seekingalpha.com published the news titled: “SeaWorld looks to outlast Blackfish blowback” on April 13, 2018. Seekingalpha.com‘s news article titled: “Seaworld: 4 Upcoming Catalysts Will Propel This Heavily Shorted Stock” with publication date: April 11, 2018 was also an interesting one.

SeaWorld Entertainment, Inc. (NYSE:SEAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts